Russia registers new drug to treat prostate cancer

The Federal Biomedical Agency (FMBA) of Russia has received national registration for a new drug for the treatment of prostate cancer, developed by FMBA specialists.

The new drug, called “Rakurs,” is a dual-action drug. First, it destroys bone metastases, prolonging the survival of patients in the late stages. The drug selectively accumulates in bone, including metastatic bone, providing a high local anti-cancer effect.

Second, the radioactive nucleus radium-223 significantly cuts or reduces pain, allowing patients to abandon strong painkillers and improve their quality of life. The drug's unique feature is that it selectively accumulates in bone tissue and destroys metastases without causing strong effects on healthy tissue.

Radionuclide [223Ra] is supplied by the Research Center “Research Institute of Nuclear Reactors” - Russia's largest nuclear energy research and testing complex, part of the Rosatom State Corporation.

The drug was developed at the FMBA Medical Oncology and Radiology Center in Dimitrovgrad. The authors say that in the future, the drug could be used to treat metastatic bone lesions and other types of cancer.

Recently, Russia also announced that it will begin clinical trials of the Enteromix cancer vaccine in 2025.

All Russian citizens are treated for all cancers free of charge, said Dr. Andrey Kaprin, chief cancer treatment specialist of the Russian Ministry of Health .

Source: https://nhandan.vn/nga-dang-ky-loai-thuoc-moi-dieu-tri-ung-thu-tuyen-tien-liet-post853023.html